The date was September 23, 2020, and President Donald Trump had just finished delivering a short set of remarks in the White House’s briefing room.
He was there to discuss Johnson & Johnson’s announcement that it had begun stage three trials on its COVID-19 vaccine. It was an opportunity for him to brag a bit about the progress made in the U.S. compared …


